ULBP1

ULBP1, also known as UL16 binding protein 1, is a protein coding gene that encodes a ligand for the NKG2D receptor on NK cells and T-cells. It plays a crucial role in the immune system by activating multiple signaling pathways, including JAK2, STAT5, ERK, and PI3K kinase/Akt. ULBP1 is highly expressed in various hematologic and solid tumors, making it a potential target for cancer immunotherapy. The protein's interaction with NKG2D leads to the activation of NK cells and T-cells, which can target and eliminate abnormal or infected cells.
In terms of drug development, there are ongoing clinical trials for drugs targeting ULBP1, such as the CAR-T therapy CYAD-01, which has shown promising results in treating hematologic malignancies. Additionally, an anti-ULBP1 monoclonal antibody is in the drug discovery phase, offering new opportunities for the treatment of multiple hematological and solid tumors.